Cite

HARVARD Citation

    Perez, T. et al. (2021). Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis. Multiple sclerosis. pp. 585-592. [Online]. 
  
Back to record